<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260828</url>
  </required_header>
  <id_info>
    <org_study_id>202102310438</org_study_id>
    <nct_id>NCT04260828</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Aspirin for the Prevention of Renal Artery Stenosis in Renal Transplantation Recipients</brief_title>
  <official_title>Efficacy and Safety Study of Aspirin for the Prevention of Renal Artery Stenosis in Renal Transplantation Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anastomotic and peripheral stenosis of the transplanted kidney artery is one of the most
      important causes of graft failure in renal transplantation. The injury of vascular intima and
      the formation of microthrombosis may play a significant role in the stenosis of transplanted
      renal artery of recipients. Inhibiting this process with aspirin may protects against the
      stenosis of transplanted renal artery.

      This is a prospective, randomized, controlled, clinical trial to investigate the efficacy and
      safety of prevention of renal artery stenosis in recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Renal Artery Stenosis</measure>
    <time_frame>2 years</time_frame>
    <description>Renal artery stenosis is defined as the presence of post-transplant renal artery stenosis in recipients evaluated by ultrasonography or renal arteriography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Allograft Function</measure>
    <time_frame>2 years</time_frame>
    <description>Renal allograft function is evaluated by mean estimated glomerular filtration rate(eGFR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Graft Loss</measure>
    <time_frame>2 years</time_frame>
    <description>The incidence of kidney failure within 2 years of transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg</intervention_name>
    <description>Daily active drug administered orally for 3 months.</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill administered orally for 3 months.</description>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients with the first renal transplantation were stable;

          2. Age â‰¥ 18 years old;

          3. Other anticoagulants and non steroidal anti-inflammatory drugs were not taken at the
             same time;

          4. In the past 3 months, there was no acute cardiovascular and cerebrovascular disease or
             infection;

          5. The rejection of acute and chronic renal transplantation was excluded;

          6. The thrombus formation of transplanted kidney was excluded.

        Exclusion Criteria:

          1. Allergic or intolerable to aspirin;

          2. Previous transplant history;

          3. Age &lt; 18;

          4. Take other anticoagulants or non steroidal anti-inflammatory drugs at the same time;

          5. History of active gastrointestinal bleeding or severe peptic ulcer;

          6. Patients with bleeding tendency or severe liver disease;

          7. Cerebral hemorrhage, cerebral infarction or acute infection occurred within 3 months;

          8. Acute and chronic rejection;

          9. Thrombus formation of transplanted renal vessels;

         10. Any condition that increases the risk of adverse events or discontinuation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiangyong Tian</last_name>
    <phone>+86-15333818352</phone>
    <email>tianxiangyong888@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tianzhong Yan</last_name>
    <phone>+86-13663718703</phone>
    <email>ytz460@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangyong Tian</last_name>
      <phone>+86-15333818352</phone>
      <email>tianxiangyong888@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

